Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

bluebird bio

FSD Pharma

Immatics NV

bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.

Why Bluebird Bio, Onconova, FSD Pharma, Immatics Are Moving Wednesday

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) increased by over 20% pre-market. This is why it happened.

ONTX Stock Price Increases Over 20% Pre-Market: Why It Happened

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q4 2020 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. Eastern time today

Onconova Therapeutics Reports Full Year 2020 Financial Results, Provides Business Update

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021

Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) increased by 4% pre-market. This is why it happened.

ONTX Stock Price Increases 4% Pre-Market: Why It Happened

NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President and Chief Executive Officer, will participate in three virtual investment conferences during the month of March, as follows:

Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March

Onconova Therapeutics (NASDAQ: ONTX) shares are trading higher today after the company announced it regained compliance with the Nasdaq listing requirement. Onconova Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing products to treat patients with cancer.

Onconova Therapeutics Shares Trading Higher Following Regained Compliance With NASDAQ Listing Requirements

Overview of Onconova Therapeutics, including pipeline, balance sheet, and recent bullish stock price action.

Onconova Therapeutics: Understanding ON12330 And Inhibition Of CDK4/6 And ARK5 In Breast Cancer

Investors are eager to hear more about the biotech's experimental cancer treatments.

Why Onconova Therapeutics Stock Soared Today

Onconova Therapeutics (ONTX) stock is on the rise Wednesday following the closing of its most recent public offering of 28.75 million shares. The post ONTX Stock: Why Biopharma Onconova Therapeutics Is Shooting Higher Today appeared first on InvestorPlace.

ONTX Stock: Why Biopharma Onconova Therapeutics Is Shooting Higher Today

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) as of 11:17 PM ET. This is why it happened.

ONTX Stock Price Increases Over 30%: Why It Happened

NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced underwritten public offering. A total of 28,750,000 shares of its common stock were sold, including 3,750,000 shares of common stock following the exercise by the underwriters of their over-allotment option, at a public offering price of $1.00 per share. The gross proceeds of the offering to the Company are $28.75 million, before deducting the underwriting discounts and commissions and other estimated offering expenses.

Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option

NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual Company update at the 2021 BIO CEO & Investor Digital Conference being held February 16-18, 2021. Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system.

Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference

NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share. The gross proceeds of the offering to the Company are expected to be $25.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, Onconova granted the underwriters a thirty-day option to purchase up to an additional 3,750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) has increased by 25% today. This is why it happened.

ONTX Stock Price Increases 25%: Why It Happened

NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain institutional accredited investors to purchase in a registered direct offering 19,550,562 shares of its common stock at a purchase price of $0.445 per share.

Onconova Therapeutics, Inc. Announces $8.7 Million Public Offering

Onconova Therapeutics (ONTX) stock is on the move Tuesday with heavy trading despite a lack of recent news from the company. The post Onconova Therapeutics: 7 Things for ONTX Stock Investors to Know About the Biopharma appeared first on InvestorPlace.

Onconova Therapeutics: 7 Things for ONTX Stock Investors to Know About the Biopharma

NEWTOWN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the filing of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for ON 123300, the Company's proprietary, differentiated, first-in-class multi-kinase inhibitor. The IND seeks permission to begin a Phase 1 trial with ON 123300 in relapsed/refractory advanced cancer including patients with HR+ HER 2- metastatic breast cancer with resistance to approved second-generation CDK4/6 inhibitors.

Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q3 2020 Results - Earnings Call Transcript

Conference call begins at 4:30 p.m. ET today

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12

Onconova Therapeutics to Provide Corporate Update and Third Quarter 2020 Financial Results on November 12, 2020

NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update during the 2020 BIO Investor Forum Digital event taking place October 13-15. Dr. Fruchtman and Avi Oler, Senior VP, Corporate Development, will be available for 1x1 meetings scheduled through the Bio Partnering system.  

Onconova Therapeutics to Present Update During the 2020 BIO Investor Forum Digital Event

Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company

News for Onconova Therapeutics Stock (ONTX)